Jump to a section

Stress & hypothalamic circuits

Current PhD · Bains Lab · Krembil Brain Institute · 2025–present
[Optional placeholder: short orienting sentence about the question being asked. Or leave blank — publications below speak for themselves once they exist.]
Manuscripts in preparation
To appear
[Once papers from this work are out, they will appear here as publication blocks. Until then, this placeholder line indicates the section is active.]

Psychedelics & seizure disorders

MSc work · Carlen Lab · Krembil Brain Institute · 2023–2025
Stacked LFP traces from LSD experiments
Lysergic acid diethylamide modulates hippocampal and cortical local field potential oscillatory rhythms in male mice
Rabinovitch BS*, Silverman N, Ji D, Shizgal D, Lewis EC, Carlen PL
Brain Res  ·  2026
This study was the first investigation of how LSD affects neural rhythms in freely-behaving mice. Using in vivo electrophysiology (electrodes implanted into the brain for intracranial EEG), we collected recordings and assessed power spectral density (PSD) in 4 key brain regions associated with psychedelic action. Overall, we found the most robust changes occurred in hippocampal regions. Perhaps most interestingly, LSD increased signal variance between animals, lending pre-clinical support to the entropic brain theory of psychedelic drug action.
Peri-event average from LSD seizure experiments
Lysergic acid diethylamide inhibits status epilepticus and mortality in a mouse model of acute kainic acid-induced motor seizures
Rabinovitch BS*, Hu W, Tang C, Silverman N, Lewis EC, Carlen PL
Next Research  ·  2025  ·  2(3): 100704
Drug-resistant epilepsy affects roughly a third of people with epilepsy, and individuals with seizure disorders have largely been excluded from psychedelic-assisted therapy trials. This study provided the first preclinical evaluation of whether LSD modulates motor seizures in mice. In the systemic kainic acid-induced seizure model, 30 μg/kg LSD pretreatment completely prevented status epilepticus and status-induced death in male mice and reduced overall seizure severity. Effects were dose- and sex-dependent. The results support continued preclinical investigation of LSD's anti-convulsant properties and inform inclusion criteria in clinical research.
Psychedelics, epilepsy, and seizures: A review
Freidel N, Kreuder L, Rabinovitch BS, Chen FY, Huang RS, Lewis EC
Frontiers in Pharmacology  ·  2023  ·  14: 1326815
Persons with spinal cord injury report peripherally dominant serotonin-like syndrome after use of serotonergic psychedelics
Karzon Abrams S, Rabinovitch BS, Zafar R, Aziz AS, Cherup NP, McMillan D, Nielson J, Lewis EC
Neurotrauma Reports  ·  2023  ·  543–550
* First author

Cannabinoids in epilepsy

Clinical research · North Toronto Neurology · 2020–2024
19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series
Chen FY, Duckman JM, Rabinovitch BS, Hannesson KJ, Lewis EC
Front Neurosci  ·  2025  ·  19: 1570531
About one third of people with epilepsy do not respond to existing anti-seizure medications, and the probability of seizure freedom with the addition of each subsequent drug trial drops substantially. Cannabis-based prescription medicines (CBPMs) have shown promise in this population, but the clinical features of responders had not been characterized. Our group reported a retrospective case series of 19 patients who achieved complete seizure freedom for at least 3 months while on CBPM therapy.
Healing of a chronic pressure injury in a patient treated with medical cannabis for pain and sleep improvement: a case report
Diaz PL, Katz TM, Langleben AC, Rabinovitch BS, Lewis EC
Wound Manag Prev  ·  2021  ·  67(10): 42–47